Clinical Trial: A Phase II Study of GC101 in NSCLC

U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT07560111) titled 'A Phase II Study of GC101 in NSCLC' on April 24.

Brief Summary: 28 participants are expected to be enrolled for the Phase II clinical trial, this trial is expected to be finished in 36 months.

Study Start Date: June 01

Study Type: INTERVENTIONAL

Condition: Non Small Cell Lung Cancer

Intervention: BIOLOGICAL: Autologous Tumor Infiltrating Lymphocytes

A tumor sample is resected from each participant and cultured ex vivo to generate tumor infiltrating lymphocytes. After lymphodepletion, patients are infused GC101 TIL followed low-dose PD-1 antibody.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Shanghai Juncell Therapeutics

P...